Meeting
2021 ASCO Annual Meeting
Outcomes of BRAF mutant metastatic melanoma (MM) patients (pts) after cessation of targeted therapy (TT) with BRAF or BRAF/MEK inhibitor(i).
Authors
Natalie Jackson
The University of Texas MD Anderson Cancer Center, Houston, TX
Natalie Jackson , Theresa Rodgers , Ida John , Denai R. Milton , Lauren Elaine Haydu , Rodabe Navroze Amaria , Adi Diab , Jennifer Leigh McQuade , Sapna Pradyuman Patel , Hussein Abdul-Hassan Tawbi , Michael K.K. Wong , Michael A. Davies , Isabella Claudia Glitza
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Melanoma/Skin Cancers
Track
Melanoma/Skin Cancers
Sub Track
Advanced/Metastatic Disease
Citation
J Clin Oncol 39, 2021 (suppl 15; abstr 9564)
DOI
10.1200/JCO.2021.39.15_suppl.9564
Abstract #
9564
Poster Bd #
Online Only
Abstract Disclosures
Similar Posters
Poster
2021 ASCO Annual Meeting
Evaluation of patients with surgically resected high-risk melanoma receiving adjuvant therapy in routine clinical practice in the United States.
First Author: Michael B. Atkins
Poster
2023 ASCO Annual Meeting
Targeting AMP kinase in melanoma: A phase I trial of phenformin with dabrafenib/trametinib.
First Author: Paul B. Chapman
Poster
2018 ASCO Annual Meeting
Dual MAPK inhibition (dMAPKi) as an effective therapeutic strategy for class II BRAF mutant (mt) metastatic melanoma (MM).
First Author: Matthew Dankner
Poster
2017 ASCO Annual Meeting
Patterns of histologic response to neoadjuvant targeted therapy in patients with BRAF mutant melanoma.
First Author: Zeynep Eroglu